

12-9156: Anti-IL17A (Cosentyx) (secukinumab biosimilar) mAb

| | |
|---------------------------|--------------------------------|
| Clonality : | Monoclonal |
| Application : | FACS |
| Reactivity : | Human |
| Alternative Name : | CTLA-8,CTLA8,IL-17,IL-17A,IL17 |
| Isotype : | IgG1 |

Description

Secukinumab (Cosentyx) is a biologic medication used to treat psoriatic arthritis, moderate to severe plaque psoriasis. Biologics are medicines that are human-made through genetic engineering techniques and closely related to a protein that occurs naturally in the body. Secukinumab blocks an inflammatory protein called IL-17, thus improving joint pain and swelling from arthritis and rash from psoriasis.

Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.

Product Info

| | |
|----------------------------|---|
| Amount : | 50 µg / 100 µg |
| Purification : | Purified from cell culture supernatant by affinity chromatography |
| Storage condition : | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. |

Application Note

FACS 1:100




Figure 1: Flow cytometry analysis with 1 µg/mL Anti-IL17A (secukinumab biosimilar) mAb (12-9156) on Expi293 cells transfected with Human IL17A protein (Blue histogram) or Expi293 transfected with irrelevant protein (Red histogram).




Figure 2: Coomassie Staining of SDS Page gel loaded with 5ug Anti-IL17A (consentyx) (secukinumab biosimilar) mAB.